lustrative of the utility of TMP in suppressing acid-catalyzed side reactions. **2-Phenyl-5,5-dimethy1-1,3-dioxane** was also smoothly cleaved (entry **4).**

The bis(ethylene acetal) of terephthalaldehyde with bromine and chlorine showed the same behavior to provide the halo esters in good yield (entry *5).* Several methods for the preparation of these esters, which are highly sought for intermediates in polymer chemistry, have been described in patented procedures.¹⁹ Most of them suffer from lengthy reaction conditions, high temperatures, difficult manipulations, and moderate yields only.¹⁹ The present procedure has the advantages of both high yield and procedural simplicity.

With respect to the regioselectivity involved in the conversion $1 \rightarrow 2$, treatment of a mixture $(3:2)^{20}$ of *cis*- and *trans*-4-methyl-2-phenyl-1,3-dioxolane $(1, R = C_6H_5; R')$ $CH₃$) with bromine in TMP at 0 °C afforded 1-methyl-2-bromoethyl benzoate and 2-methyl-2-bromoethyl benzoate (2 and 2a, $R = C_6H_5$; $R' = CH_3$; $X = Br$) in the ratio 24:1, respectively (entry 6).²¹ The same isomer distribution was found in the chlorination reaction. The bis- (propylene acetal) of terephthalaldehyde with bromine and chlorine showed a similar trend (entry **7).** This aspect coupled with the fact halogenative cleavage takes place without a radical source implies an ionic pathway indicated in Scheme I.^{2-7,15} Halide attack on the ambident cation **4** from the least hindered side accounts for the major isomer formed. High regioselectivity observed in TMP may be due tc solvation of the cation in the ion pair **4** resulting in reduced reactivity of the counterion.

In summary, TMP mediated halogenative cleavage is convenient and proceeds rapidly without added catalysts to give pure halo esters in high yields. In most cases, the reaction can be run in a homogeneous medium. Both neutral and mild reaction conditions should permit easily cleavable functional groups to remain intact. The present procedure is also significantly superior with respect to the regioselectivity than with the reported methods.²⁻⁶

Experimental Section

General Data. Melting points were determined with a Thomas-Hoover capillary melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer 727 infrared spectrophotometer. 'H NMR spectra were obtained on a Jeol MH-100 nuclear magnetic resonance spectrometer. Elemental analyses were carried out by Galbraith Laboratories. Knoxville, Tenn. Trimethyl phosphate (TMP) was distilled over P_2O_5 (bp 52-54 °C (0.5 mm)) and stored in amber-colored bottles.

Starting Materials. The starting acetals were prepared by boiling a mixture of the aldehyde (0.5 mol), glycol (0.55 mol), anhydrous benzene (100 mL), and a catalytic amount of ptoluenesulfonic acid with the removal of water (Dean-Stark). After evaporation of the solvent, the residue was distilled under vacuum. Physical data are given in Table I.

General Procedure for the Preparation of Halohydrin Esters. The reactions were run at the temperatures indicated in Table I. To a magnetically stirred solution or suspension of the acetal (0.1 mol) in 60 mL of TMP, protected from moisture, bromine (17.6 g, 0.11 mol in 50 mL of TMP)²² or chlorine (the gas was bubbled at 0 *"C* into 50 mL of TMP until 0.11 mol was absorbed) was added dropwise during 1 h. **An** exothermic reaction ensued in all the cases, and the temperature was not permitted to rise above 10 °C. During the addition, a gas $(CH_3Br$ or CH_3Cl)

was evolved. After being stirred for an additional period of time an oil separated, it was extracted with hexane $(3 \times 50 \text{ mL})$, and the combined organic extract was washed with cold water $(3 \times$ 50 mL). After being stirred with anhydrous $MgSO₄$ in a hood to expel excess bromine or chlorine, the solvent was removed in a rotoevaporator, and the residue was distilled under vacuum.

If a solid was formed on dilution with water, it was filtered, washed with cold water, and recrystallized from an appropriate solvent.

Physical data and yields are given in Table I.

Bromination of 2-Cyclohexyl-1,3-dioxolane in CC14. To a stirred solution of the acetal (15.62 g, 0.1 mol) in 50 mL of CCl_4 cooled to 0 °C was added bromine (17.6 g, 0.11 mol) dissolved in 50 mL of CCl₄ during 1 h (CaCl₂ tube). The temperature of the reaction was not allowed to rise above 8 "C by controlled addition. After the solution was stirred at room temperature for 3 h, the usual workup afforded a colorless oil (24.0 g) . ¹H NMR analysis of the reaction product showed it to be a mixture of **2** $(R = C₆H₁₁; R' = H; X = Br)$, 5, and 6. Only bromoester 2 was obtained when the above reaction was run in TMP.

Registry No. 2 ($R = C_6H_5$, $R^1 = H$, $X = Br$), 939-54-8; **2** ($R = p\text{-CH}_3C_6H_4$, $R^1 = H$, $X = Br$), 7143-95-5; **2** ($R = C_6H_{11}$, $R^1 = H$, X $\tilde{P} = \text{Br}$, 36262-27-8; **2** (R = Br(CH₂)₂-O-CO-p-C₆H₄, R¹ = H, X = Br), **2** (R = C₆H₅, R¹ = CH₃, \tilde{X} = Br), 6065-70-9; **2** (R = C₆H₅, R¹ = CH₃, $X = Cl$), 36220-92-5; **2** $(R = BrCH_2CH(CH_3)-O-CO-p-C_6H_4$, $R^1 = CH_3$, $X = Br$), 70659-69-7; **2** (R = ClCH₂CH(CH₃)-O-CO- p -C₆H₄, R¹ = CH₃, X = Cl), 70659-70-0; **5,** 70659-71-1; **6,** 70659-72-2; 2-phenyl-1,3-dioxolane, 936-51-6; **2-p-tolyl-1,3-dioxolane,** 2403-51-2; 2-cyclohexyl-1,3-dioxolane, 4362-48-5; **5,5-dimethyl-2-pheny1-1,3-dioxane,** 776-88-5; **2,2'-(1,4-phenylene)bis[l,3-dioxolane],** 5660-56-0; cis-4-methyl-2 phenyl-1,3-dioxolane, 5932-73-0; **trans-4-methyl-2-phenyl-1,3-dioxolane,** 51591-49-2; **2,2'-(1,4-phenylene)bis[4-methyl-l,3-dioxolane],** 70659-73-3; **3-bromo-2,2-dimethylpropyl** benzoate, 70659-74-4; benzaldehyde, 100-52-7; p-methylbenzaldehyde, 104-87-0; **cyclohexanecarboxaldehyde,** 2043-61-0; terephthalaldehyde, 623-27-8; ethylene glycol, 107-21-1; 2,2-dimethylpropylene glycol, 126-30-7; 1,2-propylene glycol, 57-55-6. $32676-75-8$; 2 (R = Cl(CH₂)₂-O-CO-p-C₆H₄, R¹ = H, X = Cl), 1026-93-3;

2/3-(Hydroxymethyl)penicillin

Douglas 0. Spry

The Lilly Research Laboratories, *Eli Lilly* and Company, Indianapolis, Indiana 46206

Receiued March *2,* 1979

Recent interest in 2 β -(hydroxymethyl)penicillins as possible precursors in the biosynthetic conversion of penicillins to cephalosporins¹ prompts us to report a successful synthesis of the title compound.

The first attempt to implicate the 2-(hydroxymethy1)penicillin as a possible intermediate in the biosynthesis of penicillin and cephalosporin antibiotics was reported in 1972 by Cooper.² He obtained the 2β -(hydroxymethyl)penicillin $1\hat{\beta}$ -oxide 1 and the corresponding lactone 2 by the oxidation of the thiazolidine azetidinone **3** (Scheme I).

Thus the corresponding 2-(hydroxymethy1)penicillin sulfides were not isolated and the yield of **1** and **2** was less than 5% ³

Morin et al.⁴ first reported the derivatization of the β -methyl group in penicillin by obtaining 2 β -(acetoxymethy1)penicillins from the Pummerer rearrangement on the penicillin sulfoxide with acetic anhydride. Since then

^{(19) (}a) Netherlands Patent 108 150 *[Chem. Abstr.,* **62,** 7696f (1965)l; (b) Japanese Patent 7503 295 [*Chem. Abstr.*, 83, 27603z (1975)]; (c) U.S.
Patent 3 280 173 [*Chem. Abstr.*, 66, P 10767h (1967)].
(20) T. D. Inch and N. Williams, J. Chem. Soc. C, 263 (1970).
(21) ¹H NMR analysis was p

At room temperature, the ratio of 2:2a is 18:l.

⁽²²⁾ Bromine or chlorine do not react with TMP in the dark. See ref 17.

⁽¹⁾ J. E. Baldwin, S. R. Herchen, J. C. Clardy, K. Hirotsu, and T. S. (2) R. D. G. Cooper, *J. Am. Chem. SOC.,* **94,** 1018 (1972). Chou, *J. Org. Chem.,* **43,** 1342 (1978).

⁽³⁾ Personal communication with R. D. G. Cooper.

(4) R. B. Morin, B. G. Jackson, R. A. Mueller, E. R. Lavagnino, W. B. Scanlon, and S. L. Andrews, J. Am. Chem. Soc., 91, 1401 (1969).

many other 2β -methylenepenam derivatives have been reported including halo,⁵⁻¹¹ alkoxy,⁹ azido,⁹ sulfides,⁹ substituted amino,⁹ and nitroxy.⁶ The 2α -methylenepenam derivatives include acetoxy, $6,12,13$ halo, $6,8$ and nitroxy. 6

It seemed to us, however, that utilization of any of the above derivatives to prepare (hydroxymethy1)penicillins by displacement would result in ring expansion to the cepham system or steric problems due to the neopentyl type system of the substituted penicillins. We were thus led to consider an intramolecular type cleavage of an appropriately substituted penicillin to afford the hydroxymethyl group.

Treatment of Kamiya's' disulfide 4 with chloroacetic acid and silver acetate gave, after careful chromatography, $35-40\%$ of the 2β -(chloroacetoxymethyl)penicillin **5** along with ca. 8% cephem **6** and ca. 30% 3-(chloroacetoxy) cepham **7.** Reaction of the disulfide 4 with dichloroacetic acid under the same conditions gave very little penicillin but mainly 3-substituted cepham, while trichloroacetic acid gave no penicillin and only cepham. These results indicate the propensity of the corresponding substituted penicillins, under the reaction conditions, to rearrange to the cepham system via an episulfonium ion.

Chloroacetylamines^{14,15} and chloroacetates¹⁶ are known to react with thiourea to give S-substituted thioamidines, which then undergo intramolecular amidinolysis to give the corresponding amine or alcohol and pseudothiohydantoin. We anticipated that the chloroacetate group of *5* would react similarly with thiourea to give the corresponding hydroxy derivative. Treatment of the 2β -(chloroacetoxymethy1)penicillin **5** with **5** mol equiv of thiourea in ethanol at 60 °C for 30 min gave a 74-84% yield of crude **2p-(hydroxymethy1)penicillin 8.** Structure of the product, (hydroxymethy1)penicillin **8,** was evident from physical data. The NMR spectrum showed loss of the chloromethylene protons at δ 4.09 and the presence of a new AB pattern for the hydroxymethyl protons at *b* 3.48 and 3.76 $(J = 10 \text{ Hz})$. The IR spectrum showed the presence of hydroxyl and the β -lactam. Mass spectrum showed a molecular ion at m/e 501 with a strong peak at m/e 483 (M – 18). Oxidation of 8 with 1 equiv of m-CPBA gave a high yield of the **2/3-(hydroxymethyl)penicillin** 1β -oxide 9, which proved identical (TLC and NMR) with material obtained from the thiourea cleavage (65-75%) of the 2β -(chloroacetoxymethyl)penicillin 1β -oxide 10 (Scheme 11).

Although 9 could be purified by silica gel chromatography and subsequent crystallization, the corresponding sulfide **8** proved unstable to silica gel chromatography, giving the lactone 11. A similar reaction with a 3β hydroxycepham on silica gel chromatography has been observed by Gutowski et al." and indeed, when **7** was treated with thiourea followed by silica gel chromatography, the lactone 12 was isolated. The difference in stability of **8** and 9 clearly indicates the stabilizing effect of hydrogen bonding between the hydroxyl group and the sulfoxide function in compound 9 (Scheme 111).

Oxidation of the sulfide of **5** with ozone18 gave a low yield of the α -sulfoxide 13 which was thermally epimerized¹² to the α -(chloroacetoxymethylene)penicillin 1 β -oxide 14. However, because of the low yield of 13 it was not feasible to cleave 14 with thiourea to give the corresponding α -(hydroxymethy1)penicillin (Scheme IV).

Removal of the p-nitrobenzyl ester function from **8** and 9 by hydrogenolysis gave the corresponding acids 15 and 16 which were biologically less active than the parent penicillin.

Experimental Section

 p -Nitrobenzyl 2 β -(Chloroacetoxymethyl)-6-(phenoxyacetamid0)penicillinate *(5).* A mixture of 0.651 g (1.0 equiv) of the disulfide **4,** 0.340 g of AgOAc (2.08 equiv), and 4.1 g of $CICH_2CO_2H$ (43.5 equiv) in 15 mL of CH_2Cl_2 was allowed to stir at room temperature for 4 h. The reaction mixture was filtered and the filtrate was washed with aqueous NaHCO₃ and brine, dried (NaSO₄), and chromatographed on silica gel using a toluene-ethyl acetate gradient to give 0.037 g of 6, 0.20 g of 5, and 0.17 g of **7.** *5:* NMR (CDCl,) *6* 1.46 (s, 3, a-Me), 3.95, 4.40 (AB, $H₅$), 5.68 (q, $J = 4$, 10 Hz, 1, H_e); IR (CHCl₃) 1790 cm⁻¹ (β -lactam). $J = 13$ Hz, 2, CH₂OC(O)CH₂Cl), 4.09 (s, 2, CH₂Cl), 4.56 (s, 2, PhOCH2) **4.82 (s,** 1, H3), 5.28 (s, 2, PNB), 5.60 (d, *J* = **4** Hz, 1,

 p -Nitrobenzyl 2 β -(Chloroacetoxymethyl)-6-(phenoxyacetamid0)penicillin I@-Oxide **(IO).** Oxidation of *5* was done in CH_2Cl_2 at 5 °C by dropwise addition of 1.05 equiv of *m*chloroperbenzoic acid. After 30 min the solution was washed with $NaHCO₃, H₂O, and brine, dried, $(Na₂SO₄)$ and chromatographed$ on silica gel using toluene-ethyl acetate gradient to give 63% 1β -oxide **10:** NMR (CDCl₃) δ 1.22 (s, 3, α -Me), 4.15 (s, 2, CH₂Cl), 4.40, 4.83 (AB, $J = 14$ Hz, 2, $CH_2OC(O)CH_2Cl$), 4.55 (s, 2, PhOCH₂), 4.83 (s, 1, H₃), 5.13 (d, $J = 4$ Hz, 1, H₅), 5.35 (s, 2, PNB), 6.20 (q, $J = 4$, 10 Hz, 1, H_e); IR (CHCl₃) 1795 cm⁻¹ (β -lactam).

 p -Nitrobenzyl 2 β -(Chloroacetoxymethyl)-6-(phenoxyacetamido)penicillin 1α -Oxide (13). A solution of the sulfide *5* (0.461 g) in 30 mL of acetone/l2 mL of water was ozonized with excess ozone (1.59 mm/min) at -3 °C for 15 min. The solution was evaporated to dryness, taken up in CH_2Cl_2 , and dried with $Na₂SO₄$ and then chromatographed on silica gel using a toluene-ethyl acetate gradient to give the la-oxide **13** in 12% yield as a froth: NMR (CDCl₃) δ 1.31 (s, α -Me), 4.18 (s, CH₂Cl), 4.59 (s, PhOCH₂), 4.85 (s, H₃), 5.39 (br, PNB, H₅, H₆); IR (CHCl₃) 1780 cm⁻¹ (β -lactam).

⁽⁵⁾ S. Kukolja and S. R. Lammert, J. Am. Chem. Soc., 94, 7169 (1972).
(6) S. Kukolja, S. R. Lammert, M. R. Gleissner, and A. I. Ellis, J. Am. Chem. Soc., 97, 3192 (1975).

⁽⁷⁾ T. Kamiya, T. Teraji, **Y.** Saito, M. Hashimoto, 0. Nakaguchi, and T. Oku, *Tetrahedron Lett.,* 3001 (1973).

⁽⁸⁾ **H.** Tanida, T. Tsuji, T. Tsushima, H. Ishitobi, T. Irie, T. Yano, H. Matsumura, and K. Tori, *Tetrahedron Lett.,* 3303 (1975).

⁽⁹⁾ T. Kamiya, T. Teraji, M. Hashimoto, 0. Nakaguti, and T. Oku, U. *S.* Patent 3 954 732 (1976).

⁽¹⁰⁾ T. Kamiya, **Y. Saito,** T. Teraji, 0. Nakaguti, T. Oku, H. Nakamora, and M. Hashimota, U. *S.* Patent, 4 009 159 (1977).

⁽¹¹⁾ S. J. Eagle and J. Kitchin, *Tetrahedron Lett.*, 4703 (1978).

(12) D. O. Spry, *J. Am. Chem. Soc.*, 92, 5006 (1970).

(13) D. O. Spry, *J. Chem. Soc.*, Chem. Commun., 259 (1973).

(14) J. D. Cocker, B. R. Cowley, J. *Soc.,* 5015 (1965). (15) M. Masaki, T. Kitahara, H. Kurita, and M. Ohta, *J. Am. Chem.*

SOC., 90, 4508 (1968).

⁽¹⁶⁾ **A.** F. Cook and D. T. Maichuk, *J. Org. Chem.,* **35,** 1940 (1970).

⁽¹⁷⁾ G. E. Gutowski, C. M. Daniels, and R. D. G. Cooper, *Tetrahedron Lett.,* 3429 (1971).

⁽¹⁸⁾ D. *0.* Spry, *J. Org. Chem.,* **37,** 793 (1972).

Scheme I1

12 (212-213 "C)

p-Nitrobenzyl 2α -(Chloroacetoxymethyl)-6-(phenoxy- **Dibenz[a,h]anthracene acetamido)penicillin 10-Oxide (14).** Thermal inversion of **13** in refluxing dichloroethane for 1 h gave 14: NMR (CDCl₃) δ 1.76 $(s, \beta-\text{Me})$, 4.18 (s, CH_2Cl) , 4.56 $(s, \overrightarrow{PhOCH_2})$, 4.84 (s, H_3) , 5.32 (br, PNB, H₅), 6.15 (q, $J = 4$, 10 Hz, H₆); IR (CHCl₃) 1790 cm⁻¹ $(\beta$ -lactam).

p-Nitrobenzyl 2β-(Hydroxymethyl)-6-(phenoxyacet**amido)penicillinate (8).** The chloroacetoxymethyl sulfide **5** (1.55 g, 1.0 equiv) and 1.02 g (5.0 equiv) of thiourea in 60 mL of EtOH were heated at 60 °C for 30 min. The mixture was then evaporated to dryness, taken up in EtOAc-H₂O, washed with H₂O and brine, penicillin as a froth: NMR (CDCl₃) δ 1.38 (s, 3, α -Me), 3.48, 3.76 $(AB, J = 10 \text{ Hz}, 2, \text{CH}_2\text{OH}), 4.52 \text{ (s, 2, PhOCH}_2), 4.88 \text{ (s, 1, H}_3),$ 5.30 (s, 2, PNB), 5.6 (m, 2, H₅, H₆); IR (CHCl₃) 1780 cm⁻¹ (β lactam); mass spectrum m/e 501, 483 (M - 18). to dryness, taken up in EtOAc-H₂O, washed with H₂O and brine,
dried (Na₂SO₄), and evaporated to 1.11 g of (hydroxymethyl)-
carcinogenic activity,¹⁻⁵ considerable progress has been

 p -Nitrobenzyl 2 β -(Hydroxymethyl)-6-(phenoxyacetamido)penicillin 1 β -Oxide (9). The chloroacetoxymethyl oxide 13 (2.192 g, 1.0 equiv) and 2 equiv (0.560 g) of thiourea were heated at 60 'C for 1 h in 100 mL of EtOH. The mixture was worked up as above in *8* followed by silica gel chromatography using a toluene-ethyl acetate gradient to give 1.405 g of 9 as a white froth.

Scheme III C rystallization from $CH₂Cl₂$ -hexane gave white needles: mp 155-156 °C; NMR (CDCI₃) δ 1.16 (s, 3, α -Me), 3.3 (br, 1, OH), 4.13 (s, 2, CH₂OH), 4.50 (s, 2, PhOCH₂), 4.95 (s, 1, H₃), 5.02 (d, $J = 4$ Hz, 1, H₅), 5.30 **(s, 2, PNB)**, 6.10 **(q,** $J = 4$ **, 10 Hz**, 1, H₆); *'0,* IR (CHCl,) 1795 cm-' (P-lactam); mass spectrum *m/e* 483 (M - 18). Anal. Calcd for C₂₃H₂₃N₃O₉S: C, 53.38; H, 4.48; N, 8.12. Found: C, 53.65; H, 4.28; N, 7.97.

p-Nitrobenzyl 5-(phenoxyacetamido)-3-oxa-9-thia-7 azabicyclo[4.2.1]nonane-8-carboxylate (11) was obtained as a white froth from silica gel chromatography of **8:** NMR (CDC13) δ 1.33 (s, 3, Me), 3.8 (br, 1, NH), 4.20 (s, 1, H₃), 4.23, 4.45 (AB, $J = 12$ Hz, 2, CH₂O), 4.55 (s, 2, PhOCH₂), 5.18 (m, 2, H₅, H₆), 5.32 (s, 2, PNB); IR (CHCl₃) 1730 cm⁻¹; mass spectrum m/e 501.

2~-(Hydroxymethyl)-6-(phenoxyacetamido)penicillin 10-oxide (16): NMR (CDC13) *6* 1.36 (s, 3, a-Me), 4.20 (s, 2, CH_2OH), 4.56 **(s, 2, PhOCH₂)**, 4.73 **(s, 1, H₃)**, 5.02 **(d, J = 4 Hz,** Scheme IV 1, H₅), 6.05 (q, $J = 4$, 10 Hz, 1, H₆); IR (CHCl₃) 1795 cm⁻¹ (β lactam).

2~-(Hydroxymethyl)-6-(phenoxyacetamido)pnicillin (15): N-CH2OCOCH₂CI
MMR (CDCl₃) 6 1.53 (s, 3, α-Me), 3.50, 3.50, 3.69 (AB, 3.50, 3.69 (AB, 3.50, 3.50, 2, H₂, 2, 2, 2, 2, 2, 2, 2, 2, 2, **c** 2 ^{CH₂C₁</sub> **C**₁^C₂^{CH₂</sub> **C**₁^C₂^{CH₂^C₁^C₃^C₂^C₁^C₂^C₁^C₂^C₁^C₃^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁^C₁}}}

> **Registry No.** 4, 70850-41-8; **5,** 70850-42-9; **6,** 28974-31-4; 7, 70850-43-0; 8,70850-44-1; 9,70850-45-2; 10,70850-46-3; 11,70850-47-4; **13,** 70878-66-9; 14, 70850-48-5; **15,** 70850-49-6; **16,** 70850-50-9.

14 **Synthesis of Some Non-K-Region Derivatives of**

Nitya G. Kundu

School of Pharmacy LACIUSC Cancer Research Laboratory, University of Southern California, Los Angeles, California 90033

Received January **3,** I979

Since polycyclic hydrocarbons have been shown to have made to elucidate the mOlecUlar mechanism **of** chemical carcinogenesis due to these hydrocarbons and related

(1) E. L. Keenaway and I. Hieger, *Brit. Med. J.,* 1, 1044 (1930). (2) J. W. Cook, I. Hieger, E. L. Keenaway, and W. V. Mayneord, *hoc.*

(4) H. Burrows, *Proc.* R. *SOC. London,* Ser. *R,* 3, 238 (1932). (5) G. Barry and J. W. Cook, *Am. J. Cancer,* **20,** 58 (1934).

⁽³⁾ H. Burrows, I. Hieger, and E. L. Keenaway, *Am. J. Cancer,* **16,57** *R. London, Ser. Bt 3v* **456** (1932).

^{(1932).}